Moreover, multimodal approaches—combining neuroimaging (e.g., Tau PET), cerebrospinal fluid biomarkers, and transcriptomic/phosphoproteomic profiling—will be essential to delineate opioid-specific contributions to Tauopathy and guide targeted interventions in opioid-related cognitive decline. This evidence concerns the gene MAPT and Mental deterioration.